BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 38113868)

  • 1. Fundus Autofluorescence Patterns in Subretinal Hemorrhages Associated with Neovascular Age-Related Macular Degeneration.
    Nawrocka ZA; Nawrocki J
    Ophthalmologica; 2024; 247(1):58-64. PubMed ID: 38113868
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of pigment epithelial detachment in AMD with submacular hemorrhage treated with vitrectomy and subretinal co-application of rtPA and anti-VEGF.
    Treumer F; Wienand S; Purtskhvanidze K; Roider J; Hillenkamp J
    Graefes Arch Clin Exp Ophthalmol; 2017 Jun; 255(6):1115-1123. PubMed ID: 28280989
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Displacement of Submacular Hemorrhage Using Subretinal Cocktail Injection versus Pneumatic Displacement: A Real-World Comparative Study.
    Szeto SKH; Tsang CW; Mohamed S; Lee GKY; Lok JKH; Hui VWK; Tsang KK; Chen LJ; Brelen M; Lai TYY
    Ophthalmologica; 2024; 247(2):118-132. PubMed ID: 38408445
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Management of submacular massive haemorrhage in age-related macular degeneration: comparison between subretinal transplant of human amniotic membrane and subretinal injection of tissue plasminogen activator.
    Caporossi T; Bacherini D; Governatori L; Oliverio L; Di Leo L; Tartaro R; Rizzo S
    Acta Ophthalmol; 2022 Aug; 100(5):e1143-e1152. PubMed ID: 34609787
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vitrectomy, subretinal Tissue plasminogen activator and Intravitreal Gas for submacular haemorrhage secondary to Exudative Age-Related macular degeneration (TIGER): study protocol for a phase 3, pan-European, two-group, non-commercial, active-control, observer-masked, superiority, randomised controlled surgical trial.
    Jackson TL; Bunce C; Desai R; Hillenkamp J; Lee CN; Lois N; Peto T; Reeves BC; Steel DH; Edwards RT; van Meurs JC; Wafa H; Wang Y
    Trials; 2022 Jan; 23(1):99. PubMed ID: 35101110
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pneumatic Displacement of Submacular Hemorrhage with Subretinal Air and Tissue Plasminogen Activator: Initial United States Experience.
    Sharma S; Kumar JB; Kim JE; Thordsen J; Dayani P; Ober M; Mahmoud TH
    Ophthalmol Retina; 2018 Mar; 2(3):180-186. PubMed ID: 31047581
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Management of thick submacular hemorrhage with subretinal tissue plasminogen activator and pneumatic displacement for age-related macular degeneration.
    Chang W; Garg SJ; Maturi R; Hsu J; Sivalingam A; Gupta SA; Regillo CD; Ho AC
    Am J Ophthalmol; 2014 Jun; 157(6):1250-7. PubMed ID: 24531021
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Timing of Large Submacular Hemorrhage Secondary to Age-Related Macular Degeneration Relative to Anti-VEGF Therapy.
    Matsunaga DR; Su D; Sioufi K; Obeid A; Wibbelsman T; Ho AC; Regillo CD
    Ophthalmol Retina; 2021 Apr; 5(4):342-347. PubMed ID: 32763426
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of subretinal versus intravitreal injection of recombinant tissue plasminogen activator with gas for submacular hemorrhage secondary to wet age-related macular degeneration: treatment outcomes and brief literature review.
    Tranos P; Tsiropoulos GN; Koronis S; Vakalis A; Asteriadis S; Stavrakas P
    Int Ophthalmol; 2021 Dec; 41(12):4037-4046. PubMed ID: 34331185
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Surgery, Tissue Plasminogen Activator, Antiangiogenic Agents, and Age-Related Macular Degeneration Study: A Randomized Controlled Trial for Submacular Hemorrhage Secondary to Age-Related Macular Degeneration.
    Gabrielle PH; Delyfer MN; Glacet-Bernard A; Conart JB; Uzzan J; Kodjikian L; Arndt C; Tadayoni R; Soudry-Faure A; Creuzot Garcher CP
    Ophthalmology; 2023 Sep; 130(9):947-957. PubMed ID: 37088447
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sequential tissue plasminogen activator, pneumatic displacement, and anti-VEGF treatment for submacular hemorrhage.
    Bardak H; Bardak Y; Erçalık Y; Erdem B; Arslan G; Timlioglu S
    Eur J Ophthalmol; 2018 May; 28(3):306-310. PubMed ID: 29148027
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Subretinal Coapplication of Tissue Plasminogen Activator and Bevacizumab with Concurrent Pneumatic Displacement for Submacular Hemorrhages Secondary to Neovascular Age-Related Macular Degeneration.
    Avcı R; Mavi Yıldız A; Çınar E; Yılmaz S; Küçükerdönmez C; Akalp FD; Avcı E
    Turk J Ophthalmol; 2021 Feb; 51(1):38-44. PubMed ID: 33631914
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tissue plasminogen activator-assisted vitrectomy for submacular hemorrhage due to age-related macular degeneration.
    Gok M; Karabaş VL; Aslan MS; Kara Ö; Karaman S; Yenihayat F
    Indian J Ophthalmol; 2017 Jun; 65(6):482-487. PubMed ID: 28643713
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pars plana vitrectomy and subretinal tissue plasminogen activator for large exudative submacular hemorrhage: a case series.
    Patikulsila D; Winaikosol P; Choovuthayakorn J; Watanachai N; Chaikitmongkol V; Kunavisarut P
    BMC Ophthalmol; 2022 Oct; 22(1):411. PubMed ID: 36303103
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison between different techniques for treatment of submacular haemorrhage due to Age-Related Macular Degeneration.
    Kishikova L; Saad AAA; Vaideanu-Collins D; Isac M; Hamada D; El-Haig WM
    Eur J Ophthalmol; 2021 Sep; 31(5):2621-2624. PubMed ID: 32993349
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TISSUE PLASMINOGEN ACTIVATOR FOR SUBFOVEAL HEMORRHAGE DUE TO AGE-RELATED MACULAR DEGENERATION: Comparison of 3 Treatment Modalities.
    Fassbender JM; Sherman MP; Barr CC; Schaal S
    Retina; 2016 Oct; 36(10):1860-5. PubMed ID: 26945238
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Naïve subretinal haemorrhage due to neovascular age-related macular degeneration. pneumatic displacement, subretinal air, and tissue plasminogen activator: subretinal vs intravitreal aflibercept-the native study.
    Iglicki M; Khoury M; Melamud JI; Donato L; Barak A; Quispe DJ; Zur D; Loewenstein A
    Eye (Lond); 2023 Jun; 37(8):1659-1664. PubMed ID: 36038720
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic factors for visual acuity improvement after treatment of submacular hemorrhage secondary to exudative age-related macular degeneration.
    Barayev E; Tiosano A; Zlatkin R; Elul R; Dotan A; Hadayer A; Gal-Or O; Ehrlich R
    Eur J Ophthalmol; 2024 May; 34(3):825-833. PubMed ID: 37715632
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Management of submacular hemorrhage with intravitreal versus subretinal injection of recombinant tissue plasminogen activator.
    Hillenkamp J; Surguch V; Framme C; Gabel VP; Sachs HG
    Graefes Arch Clin Exp Ophthalmol; 2010 Jan; 248(1):5-11. PubMed ID: 19669780
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term outcome of subretinal coapplication of rtPA and bevacizumab followed by repeated intravitreal anti-VEGF injections for neovascular AMD with submacular haemorrhage.
    Treumer F; Roider J; Hillenkamp J
    Br J Ophthalmol; 2012 May; 96(5):708-13. PubMed ID: 22174095
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.